SERA PROGNOSTICS, INC. - 10-Q Summary
Business Context and Reporting Period
Company: Sera Prognostics, Inc. (SERA)
Reporting Period: Quarter and six months ended June 30, 2026
Business Overview: Sera is a women's health company focused on developing and commercializing blood-based biomarker tests, primarily the PreTRM test, which predicts the risk of spontaneous preterm birth. The company operates a CLIA-certified laboratory in Salt Lake City, Utah. It is classified as an Emerging Growth Company and a Smaller Reporting Company.
Key Financial Metrics
| Metric (in thousands) | Three Months Ended June 30, 2026 |
Six Months Ended June 30, 2026 |
Six Months Ended June 30, 2025 |
|---|---|---|---|
| Revenue | $30 | $44 | $55 |
| Net Loss | $(9,139) | $(17,538) | $(16,233) |
| Net Loss Per Share (Basic/Diluted) | $(0.18) | $(0.35) | $(0.36) |
| Operating Expenses | $10,034 | $19,408 | $18,625 |
| Cash and Cash Equivalents | $4,398 | $4,398 | $5,016 |
| Marketable Securities | $75,860 | $75,860 | $91,836 |
| Total Liquidity (Cash + Securities) | $80,258 | $80,258 | $96,852 |
| Accumulated Deficit | $(329,260) | $(329,260) | $(296,027) |
Note: Revenue is minimal as the company is in the commercialization phase. Gross margin is negative due to high fixed costs relative to low revenue volume.
Material Changes vs. Prior Period
- Revenue: Revenue decreased by $11,000 (20%) for the six months ended June 30, 2026, compared to the same period in 2025 ($44k vs. $55k). Quarterly revenue increased slightly ($30k vs. $17k).
- Net Loss: Net loss increased by $1.3 million for the six-month period ($17.5M vs. $16.2M) and by $1.1 million for the quarter ($9.1M vs. $8.0M).
- Operating Expenses: Total operating expenses increased by $783,000 for the six-month period. Selling and marketing expenses rose significantly by $964,000 due to strategic hiring for commercialization. Research and development expenses decreased by $148,000.
- Liquidity: Total cash and marketable securities decreased by approximately $16.6 million compared to the prior year period, primarily due to operating losses and reduced investment income.
- Restructuring: In May 2026, the company announced a workforce reduction of 14 employees (approx. 18% of the workforce), incurring approximately $1.3 million in one-time severance and termination costs.
Guidance, Outlook, and Risks
- Commercialization Strategy: Management is shifting focus from R&D to commercialization of the PreTRM test. They anticipate meaningful cost savings in 2027, with projected decreases of 35% in R&D and 25% in G&A cash expenses.
- Liquidity Outlook: Management expects existing cash and cash equivalents to fund operating expenses and capital expenditures through 2029.
- Key Developments:
- Illinois Medicaid: Illinois enacted legislation requiring Medicaid coverage for proteomic blood tests for preterm birth risk, covering approx. 50,000 annual births.
- PRIME Study: Recent publications highlighted a 20% reduction in NICU admissions and significant reductions in neonatal morbidity/mortality. A subgroup analysis showed particular efficacy for first-time mothers.
- Payer Engagement: Active discussions with over 20 payer opportunities across 20+ states.
- Risks:
- Capital Needs: Continued reliance on equity or debt financing if commercialization does not generate sufficient revenue.
- Reimbursement: Uncertainty regarding third-party payer coverage and reimbursement rates for the PreTRM test.
- Regulatory: Potential changes in FDA regulation of Laboratory Developed Tests (LDTs) and state laboratory licensure requirements.
- Restructuring Risks: Potential loss of institutional knowledge and morale following recent workforce reductions.
Investor Verification Checklist
- Cash Runway: Verify the accuracy of the projection that current liquidity ($80.3M) is sufficient to fund operations through 2029 given the burn rate.
- Revenue Recognition: Review the deferred revenue balance ($20.3M) related to the Elevance Health agreement and the specific terms for revenue recognition.
- Restructuring Costs: Confirm the timing and total amount of the $1.3M severance costs and their impact on future quarters.
- Illinois Medicaid Implementation: Assess the timeline for actual reimbursement processing following the June 2026 legislative mandate.
- Stock-Based Compensation: Monitor the $5.9M in unrecognized stock-based compensation expense, which represents a significant future non-cash cost.